Hannah R. Abrams
@hannahrabrams.bsky.social
Heme/Onc fellow at Fred Hutch, hoping to reduce costs & improve patient/caregiver experiences in cancer care. Social Media Editor @ JCO OP. Views are my own. #MedSky
Important aspect of recent lung cancer screening discussion prompted by the new JAMA Open article: even if we were to keep pack-year criteria, current cutoffs are inadequate & disproportionately rule-out Black patients.
From 2019 analysis: ~30% sensitivity, 80% specificity
From 2019 analysis: ~30% sensitivity, 80% specificity
November 25, 2025 at 8:39 PM
Important aspect of recent lung cancer screening discussion prompted by the new JAMA Open article: even if we were to keep pack-year criteria, current cutoffs are inadequate & disproportionately rule-out Black patients.
From 2019 analysis: ~30% sensitivity, 80% specificity
From 2019 analysis: ~30% sensitivity, 80% specificity
Reposted by Hannah R. Abrams
Sorry @erictopol.bsky.social it doesn't. All participants were normal coffee drinkers. Therefore, the coffee-drinker arm is the Control arm. The intervention of going cold turkey increased the hazard of AF by 64% (100/0.61). The whole report is written from the wrong perspective.
November 10, 2025 at 12:02 AM
Sorry @erictopol.bsky.social it doesn't. All participants were normal coffee drinkers. Therefore, the coffee-drinker arm is the Control arm. The intervention of going cold turkey increased the hazard of AF by 64% (100/0.61). The whole report is written from the wrong perspective.
When patients with metastatic cancer are admitted to the hospital, many people optimistically say "you'll go to rehab and get stronger and we'll see you back!"
IMO this data suggests we need 1) better care coord with SNF & 2) more honest discussion of what outcomes may be after.
IMO this data suggests we need 1) better care coord with SNF & 2) more honest discussion of what outcomes may be after.
November 21, 2025 at 4:53 AM
When patients with metastatic cancer are admitted to the hospital, many people optimistically say "you'll go to rehab and get stronger and we'll see you back!"
IMO this data suggests we need 1) better care coord with SNF & 2) more honest discussion of what outcomes may be after.
IMO this data suggests we need 1) better care coord with SNF & 2) more honest discussion of what outcomes may be after.
Wow. Data from @n8pennell.bsky.social & team #JCOOP confirming the care fragmentation many of us see in real life.
Patients with metastatic NSCLC whose docs felt it was reasonable for them to restart treatment after rehabbing at a SNF:
- Only 54% saw outpt onc again
- 31% restarted tx
Patients with metastatic NSCLC whose docs felt it was reasonable for them to restart treatment after rehabbing at a SNF:
- Only 54% saw outpt onc again
- 31% restarted tx
November 21, 2025 at 4:50 AM
Wow. Data from @n8pennell.bsky.social & team #JCOOP confirming the care fragmentation many of us see in real life.
Patients with metastatic NSCLC whose docs felt it was reasonable for them to restart treatment after rehabbing at a SNF:
- Only 54% saw outpt onc again
- 31% restarted tx
Patients with metastatic NSCLC whose docs felt it was reasonable for them to restart treatment after rehabbing at a SNF:
- Only 54% saw outpt onc again
- 31% restarted tx
Reposted by Hannah R. Abrams
"our report highlights the need for our professional societies and abstract reviewers to cultivate greater awareness and adherence to patient-respectful language"
Original research from @narjustflorezmd.bsky.social @jco-asco.bsky.social @ascocancer.bsky.social
ascopubs.org/doi/10.1200/...
Original research from @narjustflorezmd.bsky.social @jco-asco.bsky.social @ascocancer.bsky.social
ascopubs.org/doi/10.1200/...
November 20, 2025 at 3:38 PM
"our report highlights the need for our professional societies and abstract reviewers to cultivate greater awareness and adherence to patient-respectful language"
Original research from @narjustflorezmd.bsky.social @jco-asco.bsky.social @ascocancer.bsky.social
ascopubs.org/doi/10.1200/...
Original research from @narjustflorezmd.bsky.social @jco-asco.bsky.social @ascocancer.bsky.social
ascopubs.org/doi/10.1200/...
Reposted by Hannah R. Abrams
free study idea! i’ve found myself avoiding the mychart app this year because it immediately showers me with notices about my medical debt, including when i try to schedule appointments. can’t help but wonder whether this is adversely affecting care and/or outcomes for vulnerable patients
November 19, 2025 at 5:14 PM
free study idea! i’ve found myself avoiding the mychart app this year because it immediately showers me with notices about my medical debt, including when i try to schedule appointments. can’t help but wonder whether this is adversely affecting care and/or outcomes for vulnerable patients
Woah! 41% of stage I/IIA dMMR colon cancers could be overstaged by CT imaging. May need better ways to upfront stage (MRI, ctDNA?) in the neoadjuvant ICI era. #GIOnc #OncSky #MedSky #JCOOP
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Accuracy of Computed Tomography Staging of Mismatch Repair-Deficient Colon Cancer | JCO Oncology Practice
PURPOSEThis study assesses the accuracy of radiographic clinical staging by computed tomography (CT) of mismatch repair-deficient (dMMR) colon cancer, given emerging data for neoadjuvant immune…
ascopubs.org
November 20, 2025 at 4:23 AM
Woah! 41% of stage I/IIA dMMR colon cancers could be overstaged by CT imaging. May need better ways to upfront stage (MRI, ctDNA?) in the neoadjuvant ICI era. #GIOnc #OncSky #MedSky #JCOOP
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Reposted by Hannah R. Abrams
We also need to know *which* subsidies are in play. As I understand it:
Paragon has proposed converting CSRs to HSA contributions
Cassidy has proposed converting ePTCs to HSA contributions
Trump has proposed (I think? this is least clear) converting *all* subsidies to HSA contributions.
Paragon has proposed converting CSRs to HSA contributions
Cassidy has proposed converting ePTCs to HSA contributions
Trump has proposed (I think? this is least clear) converting *all* subsidies to HSA contributions.
Wonky but important question for understanding the effects of proposals to convert ACA premium tax credits to health savings accounts: How big would the contributions be? Would they vary by income, age, and geography in the same way as the premium tax credits?
November 19, 2025 at 3:50 PM
We also need to know *which* subsidies are in play. As I understand it:
Paragon has proposed converting CSRs to HSA contributions
Cassidy has proposed converting ePTCs to HSA contributions
Trump has proposed (I think? this is least clear) converting *all* subsidies to HSA contributions.
Paragon has proposed converting CSRs to HSA contributions
Cassidy has proposed converting ePTCs to HSA contributions
Trump has proposed (I think? this is least clear) converting *all* subsidies to HSA contributions.
If you or your caregiver are working at time of cancer diagnosis, it almost seems unfathomable how people can make it financially work. Often “good” insurance doesn’t correlate with coverage, and while there are some good support programs out there it can be a full time job in itself to set up.
And almost nobody has "cancer money” of the type you need when it’s really serious
which is why I’m increasingly skeptical thinking about how the idea that wealth is protective (which it is…until it’s not) causes us to overlook how ind. wealth, not Bezos wealth but like median white wealth,
which is why I’m increasingly skeptical thinking about how the idea that wealth is protective (which it is…until it’s not) causes us to overlook how ind. wealth, not Bezos wealth but like median white wealth,
i've half-joked about how you aren't actually rich until you have "cancer money", or enough that you can pay for treatment *and* be out of work for however long *and* maintain your or your family's basic quality of life (ie, not having to liquidate core assets like your primary residence).
November 19, 2025 at 2:47 PM
If you or your caregiver are working at time of cancer diagnosis, it almost seems unfathomable how people can make it financially work. Often “good” insurance doesn’t correlate with coverage, and while there are some good support programs out there it can be a full time job in itself to set up.
In Sept, Bishal Gyawali published in #JCOOP on the high cost of some 'more convenient' Rx formulations (peg-GCSF, oral GNRH instead of SQ/IM, combo pills)
Out now, European perspective on how to operationalize this:
ascopubs.org/doi/10.1200/...
Out now, European perspective on how to operationalize this:
ascopubs.org/doi/10.1200/...
November 19, 2025 at 3:49 AM
In Sept, Bishal Gyawali published in #JCOOP on the high cost of some 'more convenient' Rx formulations (peg-GCSF, oral GNRH instead of SQ/IM, combo pills)
Out now, European perspective on how to operationalize this:
ascopubs.org/doi/10.1200/...
Out now, European perspective on how to operationalize this:
ascopubs.org/doi/10.1200/...
I often hear "I wish we didn't have to waste these expensive meds every time a patient stops & has extra left over."
Here's what the state of Michigan did to combat this:
- Statewide cancer drug repository, 105 sites
- $26 million value/>100K pills donated to >1K pts
ascopubs.org/doi/10.1200/...
Here's what the state of Michigan did to combat this:
- Statewide cancer drug repository, 105 sites
- $26 million value/>100K pills donated to >1K pts
ascopubs.org/doi/10.1200/...
Transforming Cancer Drug Access: Insights Into Utilization and Clinician Satisfaction in a Statewide Cancer Drug Repository Network | JCO Oncology Practice
PURPOSEThe rise in high-cost cancer therapies has intensified financial strain on patients with cancer, whereas medication waste simultaneously continues to increase. This study evaluated outcomes…
ascopubs.org
November 18, 2025 at 2:04 AM
I often hear "I wish we didn't have to waste these expensive meds every time a patient stops & has extra left over."
Here's what the state of Michigan did to combat this:
- Statewide cancer drug repository, 105 sites
- $26 million value/>100K pills donated to >1K pts
ascopubs.org/doi/10.1200/...
Here's what the state of Michigan did to combat this:
- Statewide cancer drug repository, 105 sites
- $26 million value/>100K pills donated to >1K pts
ascopubs.org/doi/10.1200/...
Exciting end to #CTOS2025 with final presentation from Erica Pimenta. Could PPARγ-2 or GLP1 agonists restore differentiation in dedifferentiated liposarcoma?
November 15, 2025 at 9:43 PM
Exciting end to #CTOS2025 with final presentation from Erica Pimenta. Could PPARγ-2 or GLP1 agonists restore differentiation in dedifferentiated liposarcoma?
Can adding aromatase inhibitor (+/-LHRHa) rescue patients with #PEComa who progress after responding to mTOR inhibitor? #CTOS2025
- n=23 women
- 26% PR, 35% SD
- Time to progression generally shorter than initial mTORi response
- Some exceptions in patients with TSC1/TSC2/PTEN
- n=23 women
- 26% PR, 35% SD
- Time to progression generally shorter than initial mTORi response
- Some exceptions in patients with TSC1/TSC2/PTEN
November 14, 2025 at 4:17 PM
.@RobinL_Jones @royalmarsden presenting ChonDRAgon PhII registrational study of Ozekibart in conventional #chondrosarcoma #CTOS2025.
- No approved systemic therapies
- mPFS 5.5 mo, with 21.7% w/o prog @ 12 mo
- Activity in both IDH-WT & mut
- TRAE incl ~13% fatigue, ~6% hepatitis
- No approved systemic therapies
- mPFS 5.5 mo, with 21.7% w/o prog @ 12 mo
- Activity in both IDH-WT & mut
- TRAE incl ~13% fatigue, ~6% hepatitis
November 14, 2025 at 2:45 PM
.@RobinL_Jones @royalmarsden presenting ChonDRAgon PhII registrational study of Ozekibart in conventional #chondrosarcoma #CTOS2025.
- No approved systemic therapies
- mPFS 5.5 mo, with 21.7% w/o prog @ 12 mo
- Activity in both IDH-WT & mut
- TRAE incl ~13% fatigue, ~6% hepatitis
- No approved systemic therapies
- mPFS 5.5 mo, with 21.7% w/o prog @ 12 mo
- Activity in both IDH-WT & mut
- TRAE incl ~13% fatigue, ~6% hepatitis
#CTOS2025 Need options for pts w/ angiosarcoma who are refractory to ICI. In PhI, injected oncolytic virus w/ TGF-B trap (AdAPT-001) shows some efficacy! Notably heavily pre-tx group.
November 13, 2025 at 8:01 PM
#CTOS2025 Need options for pts w/ angiosarcoma who are refractory to ICI. In PhI, injected oncolytic virus w/ TGF-B trap (AdAPT-001) shows some efficacy! Notably heavily pre-tx group.
More data on TCRs in synovial sarcoma/MRCLS! In pooled analysis, Lete-cel (NY-ESO-1), w/ similar ORR to afami-cel (MAGEA4) & median OS 20.5 mo w/ small subset long-term responders.
Exciting to have multiple cell therapy options, need further studies to know how to seq & cross-sensitivity. #CTOS25
Exciting to have multiple cell therapy options, need further studies to know how to seq & cross-sensitivity. #CTOS25
November 13, 2025 at 7:25 PM
More data on TCRs in synovial sarcoma/MRCLS! In pooled analysis, Lete-cel (NY-ESO-1), w/ similar ORR to afami-cel (MAGEA4) & median OS 20.5 mo w/ small subset long-term responders.
Exciting to have multiple cell therapy options, need further studies to know how to seq & cross-sensitivity. #CTOS25
Exciting to have multiple cell therapy options, need further studies to know how to seq & cross-sensitivity. #CTOS25
Larotrectinib for TRK-fusion sarcomas: when it works, it works.
- 38% long-term (2 year) responders
- In responders, 73% remain without progression at 6 years, 98% OS
#CTOS2025 Next questions: When to stop? How to predict responders?
- 38% long-term (2 year) responders
- In responders, 73% remain without progression at 6 years, 98% OS
#CTOS2025 Next questions: When to stop? How to predict responders?
November 13, 2025 at 3:56 PM
Larotrectinib for TRK-fusion sarcomas: when it works, it works.
- 38% long-term (2 year) responders
- In responders, 73% remain without progression at 6 years, 98% OS
#CTOS2025 Next questions: When to stop? How to predict responders?
- 38% long-term (2 year) responders
- In responders, 73% remain without progression at 6 years, 98% OS
#CTOS2025 Next questions: When to stop? How to predict responders?
Starting with this article on ICI pricing from @thewonkologist.bsky.social and colleagues!
Do more approved drugs with the same mechanism reduce prices?
ascopubs.org/doi/10.1200/...
Do more approved drugs with the same mechanism reduce prices?
ascopubs.org/doi/10.1200/...
November 12, 2025 at 12:52 AM
Starting with this article on ICI pricing from @thewonkologist.bsky.social and colleagues!
Do more approved drugs with the same mechanism reduce prices?
ascopubs.org/doi/10.1200/...
Do more approved drugs with the same mechanism reduce prices?
ascopubs.org/doi/10.1200/...
Happy to say it's masthead official, I am joining JCO OP as a consultant editor for social media!
Our goal is to generate real conversations on the journal's work with the #OncSky #HealthPolicy experts here. I'll be sharing some of what's published in the journal & would love to hear your opinions!
Our goal is to generate real conversations on the journal's work with the #OncSky #HealthPolicy experts here. I'll be sharing some of what's published in the journal & would love to hear your opinions!
November 11, 2025 at 11:39 PM
Happy to say it's masthead official, I am joining JCO OP as a consultant editor for social media!
Our goal is to generate real conversations on the journal's work with the #OncSky #HealthPolicy experts here. I'll be sharing some of what's published in the journal & would love to hear your opinions!
Our goal is to generate real conversations on the journal's work with the #OncSky #HealthPolicy experts here. I'll be sharing some of what's published in the journal & would love to hear your opinions!
Reposted by Hannah R. Abrams
New at Can We Still Govern? New Medicaid work requirements will see an estimated 5 million lose coverage.
Small investments in in-house tech capacity could allow states to start preparing now to expand automatic renewal of clients. Here is the evidence 🧵
donmoynihan.substack.com/p/how-a-van-...
Small investments in in-house tech capacity could allow states to start preparing now to expand automatic renewal of clients. Here is the evidence 🧵
donmoynihan.substack.com/p/how-a-van-...
Lessons from Pandemic Era Medicaid Automation for Work Requirements
Small tech capacity investments offer big returns
donmoynihan.substack.com
November 10, 2025 at 2:22 PM
New at Can We Still Govern? New Medicaid work requirements will see an estimated 5 million lose coverage.
Small investments in in-house tech capacity could allow states to start preparing now to expand automatic renewal of clients. Here is the evidence 🧵
donmoynihan.substack.com/p/how-a-van-...
Small investments in in-house tech capacity could allow states to start preparing now to expand automatic renewal of clients. Here is the evidence 🧵
donmoynihan.substack.com/p/how-a-van-...
Interesting article out this week from Dr. Bishal Gyawali, arguing that we should use more superiority designs for treatment de-escalation studies in cancer.
"The burden of proof in medicine lies on more treatment."
academic.oup.com/jnci/advance...
"The burden of proof in medicine lies on more treatment."
academic.oup.com/jnci/advance...
November 7, 2025 at 10:31 PM
Interesting article out this week from Dr. Bishal Gyawali, arguing that we should use more superiority designs for treatment de-escalation studies in cancer.
"The burden of proof in medicine lies on more treatment."
academic.oup.com/jnci/advance...
"The burden of proof in medicine lies on more treatment."
academic.oup.com/jnci/advance...
Among many great talks today at @fredhutch.org HICOR Value in Cancer Care Summit, one that' I'm still thinking about on is this one re: trust in oncology, from Dr. Tony Back. His points (1/5):
November 6, 2025 at 10:37 PM
Among many great talks today at @fredhutch.org HICOR Value in Cancer Care Summit, one that' I'm still thinking about on is this one re: trust in oncology, from Dr. Tony Back. His points (1/5):